C
Charles S. Fermaintt
Researcher at University of Texas Health Science Center at San Antonio
Publications - 5
Citations - 54
Charles S. Fermaintt is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Eribulin & Immunotherapy. The author has an hindex of 2, co-authored 5 publications receiving 11 citations.
Papers
More filters
Journal ArticleDOI
Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
Susan Matthew,Qi-Yin Chen,Ranjala Ratnayake,Charles S. Fermaintt,Daniel Lucena-Agell,Francesca Bonato,Andrea E. Prota,Seok Ting Lim,Xiaomeng Wang,J. Fernando Díaz,April L. Risinger,Valerie J. Paul,María A. Oliva,Hendrik Luesch,Hendrik Luesch +14 more
TL;DR: In this paper, a novel microtubule-destabilizing cyclodepsipeptide, termed gatorbulin-1 (GB1), was discovered at the tubulin intradimer interface.
Journal ArticleDOI
Eribulin Activates the cGAS-STING Pathway via the Cytoplasmic Accumulation of Mitochondrial DNA.
TL;DR: In this paper, the microtubule destabilizer eribulin, but not the micro-tubule stabilizer paclitaxel, was shown to activate the cGAS-STING innate immune signaling pathway through the accumulation of mitochondrial DNA in the cytoplasm.
Journal ArticleDOI
Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with Immunogenic Potential
Charles S. Fermaintt,Thilini Peramuna,Shengxin Cai,Leila Takahashi-Ruiz,Jacob Nathaniel Essif,Corena V Grant,Barry R. O'Keefe,Susan L. Mooberry,Robert H. Cichewicz,April L. Risinger +9 more
TL;DR: Yuanhuacine as mentioned in this paper was identified as a potent and highly selective inhibitor of the basal-like 2 (BL2) subtype of TNBC that also promoted an antitumor associated cytokine signature in immune cells.
Proceedings ArticleDOI
Abstract P5-05-03: Eribulin treatment activates type 1 IFNs to promote a gene expression signature associated with antitumor immunity
TL;DR: Evidence is provided that distinct MTAs used for the treatment of TNBC have different immune modulatory properties and suggest that the specific immune signatures initiated by the different MTAs need to be considered for their optimal use with checkpoint inhibitors.